NL-OMON42894已完成2 期
Short-term safety, efficacy and mode of action of apremilast in moderate suppurative hidradenitis suppurativa: a randomised double-blind placebo controlled trial. - Mode of action apremilast in HS - SMASH trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •adult (>= 18 years of age) male or female patients with moderate HS according to a PGA of 3 on the 5-point HS-Physician Global Assessment (HS-PGA); HS of more than 6 months duration; have lesions in at least two anatomical locations.
排除标准
- •Contraindication for apremilast; previous use of apremilast; have any current and/or recurrent clinically significant skin condition in the treatment area other than HS; presence of other uncontrolled major disease; pregnant or lactating women
研究者
相似试验
进行中（未招募）
1 期
PDE4 inhibitor (apremilast) in pemphigoid.EUCTR2018-002564-10-NLniversitair Medisch Centrum Groningen10
已完成
2 期
Short-term safety, efficacy and mode of action of apremilast in mild to moderate cutaneous pemphigoid: a phase IIa open label single arm study.parapemphigus10014982NL-OMON49116niversitair Medisch Centrum Groningen10
招募中
不适用
PDE4 inhibitor (apremilast) in pemphigoidNL-OMON21799MCG10
已完成
不适用
Investigation of short-term efficacy and safety of 5-alpha reductase inhibitor in the patients with BPHJPRN-UMIN000025443ara Medical University200
尚未招募
3 期
Evaluation of the Safety and Efficacy of Short-term A 002 Treatment in Subjects with Acute Coronary SyndromesHeart AttackHeart Disease10082206NL-OMON34504Anthera Pharmaceuticals, Inc576